Nemaura Medical (NSDQ:NMRD) said today that it launched a study of its wearable glucose monitor in the hopes of winning regulatory approval in the U.S.
The England-based company touted positive interim data from the study, focusing on the at-home use of the sugarBeat device.
Get the full story at our sister site, Drug Delivery Business News.